Abstract
The insulin-like growth factor-I (IGF-I) signaling induces epithelial to mesenchymal transition (EMT) program and contributes to metastasis and drug resistance in several subtypes of tumors. In preclinical studies, targeting of the insulin-like growth factor-I receptor (IGF-IR) showed promising anti-tumor effects. Unfortunately, high expectations for anti-IGF-IR therapy encountered challenge and disappointment in numerous clinical trials. This review summarizes the regulation of EMT by IGF-I/IGF-IR signaling pathway and drug resistance mechanisms of targeting IGF-IR therapy. Most importantly, we address several factors in the regulation of IGF-I/IGF-IR-associated EMT progression that may be potential predictive biomarkers in targeted therapy.
Original language | English (US) |
---|---|
Article number | 6 |
Journal | Molecular cancer |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - Jan 30 2017 |
Keywords
- EMT
- IGF-I
- IGF-IR
- Metastasis
- Therapy
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Cancer Research